vs
Side-by-side financial comparison of ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) and Ballard Power Systems Inc. (BLDP). Click either name above to swap in a different company.
ASCENTAGE PHARMA GROUP INTERNATIONAL is the larger business by last-quarter revenue ($32.6M vs $17.7M, roughly 1.8× Ballard Power Systems Inc.).
Ascentage Pharma Group International is a global clinical-stage biotechnology company specializing in developing novel targeted therapies for cancers, chronic viral infections, and age-related diseases. It focuses on small molecule drugs targeting apoptosis pathways and other key oncogenic mechanisms, with operations spanning China, the U.S., and other global markets, serving patients with unmet medical needs worldwide.
Ballard Power Systems Inc. is a developer and manufacturer of proton exchange membrane (PEM) fuel cell products for markets such as heavy-duty motive, portable power, material handling as well as engineering services. Ballard has designed and shipped over 400 MW of fuel cell products to date.
AAPG vs BLDP — Head-to-Head
Income Statement — Q2 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $32.6M | $17.7M |
| Net Profit | $11.4M | $176.5M |
| Gross Margin | 90.7% | — |
| Operating Margin | — | — |
| Net Margin | — | 994.4% |
| Revenue YoY | — | — |
| Net Profit YoY | — | — |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $17.7M | ||
| Q2 25 | $32.6M | — | ||
| Q3 24 | — | $-12.3M | ||
| Q1 22 | — | $3.4M |
| Q3 25 | — | $176.5M | ||
| Q2 25 | $11.4M | — | ||
| Q3 24 | — | — | ||
| Q1 22 | — | $-22.6M |
| Q3 25 | — | — | ||
| Q2 25 | 90.7% | — | ||
| Q3 24 | — | 156.5% | ||
| Q1 22 | — | — |
| Q3 25 | — | 994.4% | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q1 22 | — | -659.1% |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $5.7M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 0.03× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $5.7M | ||
| Q2 25 | — | — | ||
| Q3 24 | — | $-6.6M | ||
| Q1 22 | — | $-26.0K |
| Q3 25 | — | 0.03× | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q1 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AAPG
| Products | $29.7M | 91% |
| Others | $2.9M | 9% |
BLDP
Segment breakdown not available.
